HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

NOVT

Novanta Inc. (Russell 2000)

Technology — Scientific & Technical Instruments

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

None 2 analysts
$141.62
+$0.82 (+0.58%)
Target: $175.00 (23.6%)
Sign in to add NOVT to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$5.04B
P/E Ratio (TTM)101.88
Forward P/E34.18
EPS (TTM)$1.39
Dividend Yield-
Profit Margin5.35%
Revenue Growth10.40%
ROE5.16%
Debt/Equity22.22
Recommendation None
Analyst Target$175.00
Analysts2
Indexes Russell 2000

Technical Indicators

RSI (14)40.2
Beta1.68
SMA 20$150.04
SMA 40$154.42
52-Week High$171.85
52-Week Low$98.27
50-Day Avg$155.09
200-Day Avg$132.20
Avg Volume533.8K
Volume491.4K

Performance Analysis

NEUTRAL

NOVT presents a mixed picture with both positive and negative indicators.

~ Trading at 59% of its 52-week range.
~ RSI at 40.2 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- P/E of 101.9 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 10.4% year-over-year.
~ Wall Street consensus is "none" from 2 analysts.
+ Average analyst target of $175.00 implies 23.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report